(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 18.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Genmab A's revenue in 2025 is $3,006,424,581.On average, 7 Wall Street analysts forecast GMAB's revenue for 2025 to be $239,535,926,863, with the lowest GMAB revenue forecast at $230,726,544,780, and the highest GMAB revenue forecast at $260,230,144,812. On average, 7 Wall Street analysts forecast GMAB's revenue for 2026 to be $283,899,675,333, with the lowest GMAB revenue forecast at $269,646,595,764, and the highest GMAB revenue forecast at $298,063,402,201.
In 2027, GMAB is forecast to generate $330,457,396,645 in revenue, with the lowest revenue forecast at $300,556,011,626 and the highest revenue forecast at $350,980,719,280.